Related Experiment Video
Updated: Aug 11, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors
1GlaxoSmithKline, Discovery Virology, Research Triangle Park, NC 27709, USA. larry.r.boone@gsk.com
Next-generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are advancing, with TMC-125 and TMC-278 showing promise for treatment-experienced patients. BILR-355 BS is in early trials, while others face discontinuation.
Area of Science:
- Virology
- Pharmacology
- Drug Development
Background:
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are crucial in HIV-1 treatment.
- There is a need for novel NNRTIs effective against resistant strains and suitable for experienced patients.
Purpose of the Study:
- To review desired attributes for next-generation HIV-1 NNRTIs.
- To highlight properties of NNRTIs in clinical development.
Main Methods:
- Review of clinical trial data and compound properties.
- Analysis of efficacy, safety, and pharmacokinetic profiles.
Main Results:
- TMC-125 is in Phase III, potentially the first NNRTI for NNRTI-experienced patients.
- TMC-278 (Phase II) shows higher potency and once-daily dosing suitability.
- BILR-355 BS (early Phase II) requires ritonavir boosting and has limited activity against resistant strains.
- Capravirine and GW-695634 development discontinued due to efficacy and safety concerns.
Conclusions:
- TMC-125 and TMC-278 represent significant advancements in NNRTI development.
- Ongoing research focuses on overcoming resistance and improving patient outcomes in HIV-1 therapy.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Inhibitors of Virion Maturation and Assembly
Inhibitors of Viral Protein Synthesis
Viruses with RNA Genomes
Retroviruses

